Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia

This study has been completed.
Sponsor:
Collaborator:
Wolfson Medical Center
Information provided by (Responsible Party):
Dr Koren Ariel, HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier:
NCT00512226
First received: August 5, 2007
Last updated: August 25, 2011
Last verified: August 2011

August 5, 2007
August 25, 2011
September 2007
December 2010   (final data collection date for primary outcome measure)
Assessment of Iron overload. [ Time Frame: December 2008 ] [ Designated as safety issue: No ]
Assessment of Iron overload.
Complete list of historical versions of study NCT00512226 on ClinicalTrials.gov Archive Site
Institute the criteria for iron chelator treatment [ Time Frame: December 2008 ] [ Designated as safety issue: No ]
Institute the criteria for iron chelator treatment
Not Provided
Not Provided
 
Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia
Clinical and Laboratory Assessment of Iron Overload in Sickle Cell Anemia and Sickle Cell Thalassemia Using T2* Cardiac MRI.

Iron overload is well study in Thalassemia patients and it's not only related to blood transfusions, since intestinal iron absorption is also increased in those patients. Sickle cell patients didn't develope significant clinical symptoms and signs of iron overload in spite frequent transfusions. The purpouse of this study is to assess the iron overload in Sickle cell anemia and Sickle cell Thalassemia patients using clinical parameters and cardiac T2*MRI in order to determine the cardiac and liver iron.

Not Provided
Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
  • Sickle Cell Anemia
  • Sickle Cell Thalassemia
  • Iron Overload
  • MRI
Other: Cardiac and Liver T2* MRI
Laboratory examinations that are routinely used in follow up of those patients and T2* MRI analysis.
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
December 2010
December 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • All the patients with Sickle cell anemia and Sickle cell Thalasemia that are currently in follow up at the Pediatric Hematology Unit

Exclusion Criteria:

  • Age below 18 years.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Israel
 
NCT00512226
0037-07-EMC
No
Dr Koren Ariel, HaEmek Medical Center, Israel
HaEmek Medical Center, Israel
Wolfson Medical Center
Principal Investigator: Ariel Koren, MD Pediatric Hematology Unit, Ha'Emek Medical Center
HaEmek Medical Center, Israel
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP